Pasar al contenido principal

EL FACTOR DE TRANSCRIPCION NRF2 EN LA PATOFISIOLOGIA DE LA ENFERMEDAD DE ALZHEIMER

PID2019-110061RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS

  • Jiménez-Villegas, José
  • Ferraiuolo, L.
  • Mead, R. J.
  • Shaw, P. J.
  • Cuadrado, Antonio
  • Rojo, Ana I.
Amyotrophic Lateral Sclerosis (ALS) is a devastating heterogeneous disease with still no convincing therapy. To identify the most strategically significant hallmarks for therapeutic intervention, we have performed a comprehensive transcriptomics analysis of dysregulated pathways, comparing datasets from ALS patients and healthy donors. We have identified crucial alterations in RNA metabolism, intracellular transport, vascular system, redox homeostasis, proteostasis and inflammatory responses. Interestingly, the transcription factor NRF2 (nuclear factor (erythroid-derived 2)-like 2) has significant effects in modulating these pathways. NRF2 has been classically considered as the master regulator of the antioxidant cellular response, although it is currently considered as a key component of the transduction machinery to maintain coordinated control of protein quality, inflammation, and redox homeostasis. Herein, we will summarize the data from NRF2 activators in ALS pre-clinical models as well as those that are being studied in clinical trials. As we will discuss, NRF2 is a promising target to build a coordinated transcriptional response to motor neuron injury, highlighting its therapeutic potential to combat ALS., This work was supported by a COEN-2018-Pathfinder phase III grant financed by the Medical Research Council Network of Centres of Excellence in Neurodegeneration (MR/S004920/1). AC and AIR are supported by PID2019-110061RB-I00 of the Spanish Ministry of Economy and Competiveness and P-024-FTPGB 2018 from Foundation Tatiana de Guzman el Bueno. PJS is supported as an NIHR Senior Investigator (NF-SI-0617-10077) and by the Sheffield NIHR Biomedical Research Centre (brc-1215-20017). JJV is holder of a master's degree fellowship (“Ayudas para el fomento de la Investigación en Estudios de Máster-UAM 2020”) funded by the Autonomous University of Madrid.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's Disease

  • Duarte, Pablo
  • Michalska, Patrycja
  • Crisman, Enrique
  • Cuadrado, Antonio
  • León, Rafael
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease. It is characterized by a complex network of physiopathological events where oxidative stress plays a central role among other factors such as neuroinflammation and protein homeostasis. Nuclear factor-erythroid 2 p45-related factor 2 (NRF2) has a multitarget profile itself as it controls a plethora of cellular processes involved in the progression of the disease. In this line, we designed a novel family of 2-(1H-indol-3-yl)ethan-1-amine derivatives as NRF2 inducers with complementary activities. Novel compounds are based on melatonin scaffold and include, among other properties, selective monoamine oxidase B (MAO-B) inhibition activity. Novel multitarget compounds exhibited NRF2 induction activity and MAO-B selective inhibition, combined with anti-inflammatory, antioxidant, and blood–brain barrier permeation properties. Furthermore, they exert neuroprotective properties against oxidative stress toxicity in PD-related in vitro. Hit compound 14 reduced oxidative stress markers and exerted neuroprotection in rat striatal slices exposed to 6-hydroxydopamine or rotenone. In conclusion, we developed a promising family of dual NRF2 inducers and selective MAO-B inhibitors that could serve as a novel therapeutic strategy for PD treatmen, This research was funded by the IS Carlos III co-financed by the European Regional Development funds (FEDER) (grant PI17/01700 to RL) by the Spanish Ministry of Economy and Competitiveness (MINECO) (grant PID2019-110061RB-I00 to A.C.) and Comunidad Autónoma de Madrid (grant B2017/BMD-3827, RL). The APC was not funde
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protective actions of nuclear factor erythroid 2-related factor 2 (NRF2) and downstream pathways against environmental stressors

  • Bayo, Mª Teresa
  • Frenis, Katie
  • Hahad, Omar
  • Steven, Sebastian
  • Cohen, Guy
  • Cuadrado, Antonio
  • Münzel, Thomas
  • Daiber, Andreas
Environmental risk factors, including noise, air pollution, chemical agents, ultraviolet radiation (UVR) and mental stress have a considerable impact on human health. Oxidative stress and inflammation are key players in molecular pathomechanisms of environmental pollution and risk factors. In this review, we delineate the impact of environmental risk factors and the protective actions of the nuclear factor erythroid 2-related factor 2 (NRF2) in connection to oxidative stress and inflammation. We focus on well-established studies that demonstrate the protective actions of NRF2 and its downstream pathways against different environmental stressors. State-of-the-art mechanistic considerations on NRF2 signaling are discussed in detail, e.g. classical concepts like KEAP1 oxidation/electrophilic modification, NRF2 ubiquitination and degradation. Specific focus is also laid on NRF2-dependent heme oxygenase-1 induction with detailed presentation of the protective down-stream pathways of heme oxygenase-1, including interaction with BACH1 system. The significant impact of all environmental stressors on the circadian rhythm and the interactions of NRF2 with the circadian clock will also be considered here. A broad range of NRF2 activators is discussed in relation to environmental stressor-induced health side effects, thereby suggesting promising new mitigation strategies (e.g. by nutraceuticals) to fight the negative effects of the environment on our health., S.Ste. holds an excellence grant and a research grant related to noise/hypertension from the Else Kroner ¨ Fresenius Foundation. T.M. is PI of the DZHK (German Center for Cardiovascular Research), Partner Site Rhine-Main, Mainz, Germany. S.Ste., T.M. and A.D. were supported by vascular biology research grants from the Boehringer Ingelheim Foundation for the collaborative research group ‘Novel and neglected cardiovascular risk factors: Molecular mechanisms and therapeutics’. A.C. holds grant PID2019-110061RB-I00 from MICINN. M.T.B.J. and K.F. hold stipends from the TransMed PhD Program of the University Medical Center Mainz funded by the Boehringer Ingelheim Foundation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Overlooked and valuable facts to know in the NRF2/KEAP1 field

  • Kopacz, Aleksandra
  • Rojo, Ana I.
  • Patibandla, Chinmai
  • Lastra, Diego
  • Piechota-Polanczyk, Aleksandra
  • Kloska, Damian
  • Jozkowicz, Alicja
  • Sutherland, Calum
  • Cuadrado, Antonio
  • Grochot-Przeczek, Anna
NRF2 (nuclear factor erythroid 2-related factor 2) is a critical regulator of the cellular stress response. It is a transcription factor that controls the expression of hundreds of genes. We will soon celebrate the thirtieth anniversary of its discovery [1]. Over the years, NRF2 and its repressor KEAP1 have become the subject of intensive research, ranging from the detailed molecular mechanisms of their activity to clinical perspectives and generating over a dozen thousand publications. This review intends to draw the attention of researchers to essential issues in the NRF2/KEAP1 field, highlighting the overlooked facts and clarifying potential misconceptions., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, and PDC2021-121421-I00) and The Autonomous Community of Madrid (grant B2017/BMD-3827). FLM enjoyed FPI contract of MINECO (FPI-2017). The National Science Centre supported this work with grants Sonata Bis No. 2016/22/E/NZ3/00405 (AGP), Opus No. 2021/43/B/NZ4/02130 (AGP), and Sonata No. 2018/31/D/NZ4/00077 (APP). AK is supported by L'Oreal for Women in Science and START Scholarship from Foundation for Polish Science. CP and CS are supported by Diabetes UK award 20/0006178.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and β-TrCP-NRF2 interactions in cancer chemoresistance

  • Srivastava, Rohini
  • Fernández-Ginés, Raquel
  • Encinar, José Antonio
  • Cuadrado, Antonio
  • Wells, Geoffrey
Drug resistance is one of the biggest challenges in cancer treatment and limits the potential to cure patients. In many tumors, sustained activation of the protein NRF2 makes tumor cells resistant to chemo- and radiotherapy. Thus, blocking inappropriate NRF2 activity in cancers has been shown to reduce resistance in models of the disease. There is a growing scientific interest in NRF2 inhibitors. However, the compounds developed so far are not target-specific and are associated with a high degree of toxicity, hampering clinical applications. Compounds that can enhance the binding of NRF2 to its ubiquitination-facilitating regulator proteins, either KEAP1 or β-TrCP, have the potential to increase NRF2 degradation and may be of value as potential chemosensitising agents in cancer treatment. Approaches based on molecular glue-type mechanisms, in which ligands stabilise a ternary complex between a protein and its binding partner have shown to enhance β-catenin degradation by stabilising its interaction with β-TrCP. This strategy could be applied to rationally discover degradative β-TrCP-NRF2 and KEAP1-NRF2 protein-protein interaction enhancers. We are proposing a novel approach to selectively suppress NRF2 activity in tumors. It is based on recent methodology and has the potential to be a promising new addition to the arsenal of anticancer agents., This article is based upon work from COST Action CA20121, supported by the European Cooperation in Science and Technology (www.cost.eu) (https://benbedphar.org/about-benbedphar/). This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00) and Generalitat Valenciana (PROMETEO/2021/059) and UCL School of Pharmacy.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

KEAP1-NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

  • Crisman, Enrique
  • Duarte, Pablo
  • Dauden, Esteban
  • Cuadrado, Antonio
  • Rodríguez-Franco, María Isabel
  • López, Manuela G.
  • León, Rafael
The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is considered the master regulator of the phase II antioxidant response. It controls a plethora of cytoprotective genes related to oxidative stress, inflammation, and protein homeostasis, among other processes. Activation of these pathways has been described in numerous pathologies including cancer, cardiovascular, respiratory, renal, digestive, metabolic, autoimmune, and neurodegenerative diseases. Considering the increasing interest of discovering novel NRF2 activators due to its clinical application, initial efforts were devoted to the development of electrophilic drugs able to induce NRF2 nuclear accumulation by targeting its natural repressor protein Kelch-like ECH-associated protein 1 (KEAP1) through covalent modifications on cysteine residues. However, off-target effects of these drugs prompted the development of an innovative strategy, the search of KEAP1-NRF2 protein–protein interaction (PPI) inhibitors. These innovative activators are proposed to target NRF2 in a more selective way, leading to potentially improved drugs with the application for a variety of diseases that are currently under investigation. In this review, we summarize known KEAP1-NRF2 PPI inhibitors to date and the bases of their design highlighting the most important features of their respective interactions. We also discuss the preclinical pharmacological properties described for the most promising compounds., Enrique Crisman is the recipient of a PFIS fellowship of ISCIII. Pablo Duarte is the recipient of an FPU fellowship of the Spanish Ministry of education. Authors gratefully acknowledge funding from IS Carlos III, Comunidad de Madrid, and Spanish Research Agency. We thank Fundación Teófilo Hernando for its continued support. All schemes were created with Biorender.com. IS Carlos III cofinanced by the European Regional Development funds (FEDER) grant number PI17/01700. General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant B2017/BMD‐3827 NRF24ADCM. Spanish Ministry of Science, Innovation and Universities (grants PID2021‐123481OB‐I00, PID2021‐122650OB‐I00, PID2021‐125986OB‐I00, PDC2021‐121421‐I00, and PID2019‐110061RB‐I00). The authors have no financial support to disclose., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanisms of NURR1 Regulation: Consequences for Its Biological Activity and Involvement in Pathology

  • García-Yagüe, Ángel Juan
  • Cuadrado, Antonio
NURR1 (Nuclear receptor-related 1 protein or NR4A2) is a nuclear protein receptor transcription factor with an essential role in the development, regulation, and maintenance of dopaminergic neurons and mediates the response to stressful stimuli during the perinatal period in mammalian brain development. The dysregulation of NURR1 activity may play a role in various diseases, including the onset and progression of neurodegenerative diseases, and several other pathologies. NURR1 is regulated by multiple mechanisms, among which phosphorylation by kinases or SUMOylation are the best characterized. Both post-translational modifications can regulate the activity of NURR1, affecting its stability and transcriptional activity. Other non-post-translational regulatory mechanisms include changes in its subcellular distribution or interaction with other protein partners by heterodimerization, also affecting its transcription activity. Here, we summarize the currently known regulatory mechanisms of NURR1 and provide a brief overview of its participation in pathological alterations., This study was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grant PID2019-110061RB-I00 for A.C.) and The Autonomous Community of Madrid (grant B2017/BMD-3827 for A.C.)., Peer reviewed